Shockwave Medical Inc (OQ:SWAV)

Mar 26, 2024 08:30 am ET
Shockwave Medical to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that the company will be participating in the 23rd Annual...
Feb 15, 2024 04:03 pm ET
Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months and full year ended...
Jan 29, 2024 08:30 am ET
Shockwave Medical Appoints Renee Gaeta as Chief Financial Officer
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today the appointment of Renee Gaeta as Chief Financial Officer...
Jan 08, 2024 08:00 am ET
Shockwave Medical Provides Quarterly Earnings Release Dates for 2024
January 8, 2024 – Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that it expects to issue quarterly earnings...
Dec 20, 2023 08:30 am ET
Shockwave Medical to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the 42nd Annual J.P....
Nov 15, 2023 08:30 am ET
Shockwave Medical to Participate in the Piper Sandler 35th Annual Healthcare Conference
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in the Piper Sandler 35th...
Nov 09, 2023 08:30 am ET
New Shockwave Coronary IVL Publication Shows Similar Outcomes in Women And Men
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today new data demonstrating excellent one-year outcomes with...
Nov 06, 2023 04:03 pm ET
Shockwave Medical Reports Third Quarter 2023 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended September 30, 2023....
Nov 03, 2023 08:00 am ET
Centers for Medicare & Medicaid Services Establishes New Category I CPT® Add-On Code for Coronary IVL
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that as part of the Calendar Year 2024 Physician Fee Schedule...
Oct 26, 2023 04:30 pm ET
Shockwave Medical Announces Details for Conference Call Discussing Third Quarter 2023 Results and Participation in Upcoming Investor Conference
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the third quarter 2023 after market close on...
Oct 20, 2023 08:30 am ET
Shockwave Medical Introduces Enhanced Coronary IVL Catheter in the United States
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today the planned U.S. introduction of the Shockwave C2+ Coronary...
Oct 19, 2023 08:30 am ET
New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that two new publications reported excellent and consistent...
Oct 04, 2023 08:00 am ET
Shockwave Medical to Livestream 2023 Investor Innovation Day
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, will host an Investor Innovation Day on Monday, October 23, 2023, from 1:00 p.m...
Sep 12, 2023 08:00 am ET
Shockwave Medical Appoints Nick West as Associate Chief Medical Officer
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Nick West, MA, MD, FRCP, FESC, FACC, has joined the...
Sep 11, 2023 04:05 pm ET
Shockwave Medical Announces Dan Puckett to Retire as CFO in 2024
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Chief Financial Officer Dan Puckett plans to retire in the...
Aug 22, 2023 08:30 am ET
Shockwave Medical to Participate in Upcoming Investor Conferences
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in two upcoming investor...
Aug 10, 2023 09:52 pm ET
Shockwave Medical Prices Upsized Private Offering of $650.0 Million of 1.00% Convertible Senior Notes Due 2028
Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave Medical”) announced today the pricing of its offering of $650.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons...
Aug 10, 2023 07:00 am ET
Shockwave Medical Announces Proposed Private Offering of $500.0 Million of Convertible Senior Notes
Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave Medical”) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2028 (the “notes”) in a...
Aug 07, 2023 04:01 pm ET
Shockwave Medical Reports Second Quarter 2023 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended June 30, 2023....
Aug 02, 2023 08:00 am ET
Centers For Medicare & Medicaid Services Creates New Hospital Inpatient Payment for Coronary Intravascular Lithotripsy
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that as part of the Fiscal Year 2024 Medicare Hospital...
Jul 18, 2023 08:30 am ET
Shockwave Medical Announces Details for Conference Call Discussing Second Quarter 2023 Results and Participation in Upcoming Investor Conference
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the second quarter 2023 after market close on...
May 31, 2023 08:00 am ET
Shockwave Medical Publishes 2022 ESG Report
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today released its 2022 ESG Report highlighting accomplishments in...
May 17, 2023 08:00 am ET
Shockwave Appoints Kevin Ballinger to Board of Directors
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Kevin Ballinger has joined its Board of Directors and will...
May 15, 2023 08:00 am ET
Shockwave Medical Launches New Coronary IVL Catheter Internationally and Enrolls First Patient in All-Female Empower Study
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced the full commercial availability of the Shockwave C2+ Coronary...
May 08, 2023 04:02 pm ET
Shockwave Medical Reports First Quarter 2023 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31,...
Apr 24, 2023 08:30 am ET
Shockwave Medical Announces Details for Conference Call Discussing First Quarter 2023 Results and Participation in Upcoming Investor Conference
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the first quarter 2023 after market close on Monday, May 8,...
Apr 11, 2023 09:31 am ET
Thinking about trading options or stock in Shockwave Medical, MicroStrategy, Tesla, PayPal, or Spotify Technology?
NEW YORK, April 11, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SWAV, MSTR, TSLA, PYPL, and SPOT.
Apr 11, 2023 08:20 am ET
Shockwave Medical Completes Acquisition of Neovasc
via NewMediaWire – Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced...
Apr 11, 2023 08:18 am ET
Shockwave Medical Completes Acquisition of Neovasc
Santa Clara, California--(Newsfile Corp. - April 11, 2023) - Shockwave Medical, Inc. (NASDAQ: SWAV) ("Shockwave"), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. ("Neovasc").
Apr 11, 2023 07:59 am ET
Shockwave Medical Completes Acquisition of Neovasc
Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (“IVL”) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of...
Mar 14, 2023 08:00 am ET
Shockwave Medical Announces U.S. Launch of New Peripheral IVL Catheter
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the full U.S. commercial availability of the Shockwave L6 Peripheral IVL...
Feb 16, 2023 04:02 pm ET
Shockwave Medical Reports Fourth Quarter and Full Year 2022 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year...
Jan 31, 2023 08:00 am ET
Updated SCAI Guidance Includes Coronary IVL as a Treatment Option in All U.S. Catheterization Labs Regardless of Surgical Backup Status
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced that coronary IVL was included in a treatment guidance document published by...
Jan 17, 2023 08:00 am ET
Shockwave Medical Announces Agreement to Acquire Neovasc
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc....
Jan 04, 2023 04:05 pm ET
Shockwave Medical Provides Quarterly Earnings Release Dates for 2023
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it expects to issue quarterly earnings releases...
Nov 22, 2022 08:30 am ET
Shockwave Medical to Participate in the Piper Sandler 34th Annual Healthcare Conference
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in the Piper Sandler 34th Annual...
Nov 16, 2022 08:30 am ET
Shockwave Medical Publishes Inaugural ESG Report
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the publication of its inaugural Environmental, Social and Governance (ESG)...
Nov 07, 2022 04:03 pm ET
Shockwave Medical Reports Third Quarter 2022 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September...
Nov 01, 2022 02:45 pm ET
Shockwave Confirms Consistent Outcomes for IVL in the Largest Prospective “Real World” Study of Patients with Heavily Calcified Peripheral Arterial Disease
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the final 1,373-patient cohort analysis from the Disrupt PAD III...
Oct 20, 2022 08:30 am ET
Shockwave Medical Announces Details for Conference Call Discussing Third Quarter 2022 Results
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the third quarter 2022 after market close on Monday,...
Sep 19, 2022 09:00 am ET
Shockwave Medical Initiates All-Female Coronary IVL Study
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, has initiated the first-ever prospective coronary intervention study consisting of all...
Aug 31, 2022 04:05 pm ET
Correcting and Replacing: Shockwave Medical to Participate in Two Upcoming Investor Conferences
In a release issued under the same headline on August 26, 2022, by Shockwave Medical, Inc. (NASDAQ: SWAV), please note that the fireside chat time for the Wells Fargo Healthcare Conference has been updated. The correct presentation time is 9:10 am...
Aug 26, 2022 08:30 am ET
Shockwave Medical to Participate in Two Upcoming Investor Conferences
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in two upcoming virtual investor...
Aug 08, 2022 04:05 pm ET
Shockwave Medical Reports Second Quarter 2022 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30,...
Jul 25, 2022 08:30 am ET
Shockwave Medical Announces Details for Conference Call Discussing Second Quarter 2022 Results and Participation in Upcoming Investor Conference
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the second quarter 2022 after market close on Monday,...
Jun 03, 2022 07:21 pm ET
Keurig Dr Pepper, VICI Properties and ON Semiconductor Set to Join S&P 500; Others to Join S&P MidCap 400, and S&P SmallCap 600
NEW YORK, June 3, 2022 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
May 23, 2022 07:30 am ET
Shockwave Medical and Genesis MedTech Obtain Regulatory Approval in China for Intravascular Lithotripsy
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, and Genesis MedTech Group announced today that they have successfully obtained approval from...
May 19, 2022 08:20 am ET
Shockwave IVL Maintains Superiority to Angioplasty in Calcified Peripheral Disease at Two Years
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that long-term data from the Disrupt PAD III trial found that superior...
May 19, 2022 07:00 am ET
Shockwave IVL Coronary Studies Demonstrate Excellent PCI Outcomes in Both Women and Men at One Year
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today new data confirming excellent one-year outcomes with coronary IVL in both...
May 09, 2022 04:02 pm ET
Shockwave Medical Reports First Quarter 2022 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31,...
Apr 27, 2022 08:00 am ET
Shockwave Medical Announces Details for Conference Call Discussing First Quarter 2022 Results and Participation in Upcoming Investor Conferences
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the first quarter 2022 after market close on Monday, May 9,...
Mar 31, 2022 08:30 am ET
Shockwave Medical Announces Global Launch of New Peripheral Intravascular Lithotripsy Catheter
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the global commercial availability of the Shockwave M5+ peripheral IVL...
Mar 30, 2022 08:30 am ET
Shockwave Medical Announces Japanese Regulatory Approval of Coronary IVL
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the Shockwave C2 Coronary IVL Catheter received the regulatory approval...
Mar 08, 2022 04:05 pm ET
Shockwave Medical Named to Fast Company's "Most Innovative Company" List
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, has been named in Fast Company’s 2022 list of the World’s Most Innovative Companies in the...
Feb 17, 2022 04:05 pm ET
Shockwave Medical Reports Fourth Quarter and Full Year 2021 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year...
Feb 04, 2022 08:00 am ET
Shockwave Medical to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company will be participating in the SVB Leerink 11th Annual Global...
Jan 04, 2022 04:03 pm ET
Shockwave Medical Provides Quarterly Earnings Release Dates for 2022
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it expects to issue quarterly earnings releases...
Nov 22, 2021 08:05 am ET
Shockwave Medical Enrolls First Patient in Disrupt BTK II Study for Long, Calcified, Below the Knee Lesions
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the start of the Disrupt BTK II post-market study to assess the safety,...
Nov 17, 2021 04:03 pm ET
Shockwave Medical to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company will be participating in the Piper Sandler 33rd Annual...
Nov 08, 2021 04:05 pm ET
Shockwave Medical Reports Third Quarter 2021 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September...
Nov 05, 2021 08:00 am ET
Shockwave Medical Unveils First One-Year Results of Coronary Intravascular Lithotripsy
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today unveiled new data confirming the safety and effectiveness of coronary IVL out to one...
Nov 03, 2021 08:00 am ET
Centers For Medicare & Medicaid Services Increases Hospital Outpatient Payment for Peripheral Intravascular Lithotripsy
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified peripheral and coronary artery disease, announced today that as part of the calendar year 2022...
Oct 14, 2021 04:23 pm ET
/C O R R E C T I O N -- Avail Medsystems/
In the news release, Avail Medsystems Honored by Goldman Sachs for Entrepreneurship, issued 14-Oct-2021 by Avail Medsystems over PR Newswire, we are advised by the company that there are updates to the second through fourth paragraphs. The complete, corrected release follows:
Oct 14, 2021 10:00 am ET
Avail Medsystems Honored by Goldman Sachs for Entrepreneurship
SANTA CLARA, Calif., Oct. 14, 2021 /PRNewswire/ -- Goldman Sachs (NYSE:GS) is recognizing Daniel Hawkins, CEO of Avail Medsystems, as one of the 100 Most Intriguing Entrepreneurs of 2021 at its Builders + Innovators Summit in Healdsburg, California.
Oct 06, 2021 12:15 pm ET
Shockwave IVL Consistently Treats “Real World” Calcium Across Multiple Peripheral Vessel Beds
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that an interim analysis from the Disrupt PAD III...
Oct 05, 2021 04:03 pm ET
Shockwave Medical to Report Third Quarter 2021 Financial Results on November 8, 2021
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the third quarter...
Aug 26, 2021 08:00 am ET
Shockwave Medical to Participate in Two Upcoming Virtual Investor Conferences
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in two upcoming virtual investor...
Aug 09, 2021 07:30 am ET
Shockwave Medical Reports Second Quarter 2021 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30,...
Jul 28, 2021 04:03 pm ET
Shockwave Medical to Present at the Canaccord Genuity 41st Annual Growth Conference
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Canaccord Genuity 41st Annual Growth...
Jul 15, 2021 04:05 pm ET
Shockwave Medical to Report Second Quarter 2021 Financial Results on August 9, 2021
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the second quarter...
Jun 28, 2021 08:30 am ET
Publications Validate Clinical Safety and Efficacy of Shockwave Intravascular Lithotripsy
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the safety, efficacy and mechanism of benefit of IVL for the treatment...
Jun 11, 2021 04:03 pm ET
CMS Grants Transitional Pass-Through (TPT) Payment for Shockwave’s Coronary IVL
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the Centers for Medicare & Medicaid Services (CMS) granted approval for...
May 10, 2021 04:05 pm ET
Shockwave Medical Reports First Quarter 2021 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31,...
Apr 27, 2021 07:59 pm ET
CMS Proposes Additional Payment for Shockwave’s Coronary IVL in Hospital Inpatient Cases
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the Centers for Medicare and Medicaid Services (CMS) published the...
Apr 27, 2021 08:30 am ET
Shockwave Medical to Participate in the Bank of America Securities 2021 Health Care Conference
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in the upcoming Bank of America...
Apr 12, 2021 04:05 pm ET
Shockwave Medical to Report First Quarter 2021 Financial Results on May 10, 2021
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the first quarter...
Mar 30, 2021 08:30 am ET
Shockwave Provides Update on U.S. Launch of Coronary IVL System
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced a preliminary forecast revenue range for the first quarter 2021, ahead of...
Mar 25, 2021 08:00 am ET
Shockwave Appoints Sara Toyloy to Board of Directors
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Sara Toyloy has joined its Board of Directors and will serve on...
Mar 22, 2021 08:00 am ET
Shockwave Announces Joint Venture in China
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company has signed an agreement to form a joint venture with...
Feb 17, 2021 04:05 pm ET
Shockwave Medical Reports Fourth Quarter and Full Year 2020 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year...
Feb 16, 2021 07:00 am ET
Shockwave Intravascular Lithotripsy FDA Approved to Treat Advanced Heart Disease
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company’s sonic pressure wave therapy received Pre-Market Approval...
Jan 19, 2021 04:05 pm ET
Shockwave Medical to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the fourth quarter...
Dec 04, 2020 08:30 am ET
Centers for Medicare & Medicaid Services Creates New Codes That Establish Specific Payment for Intravascular Lithotripsy Performed Below the Knee
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified peripheral and coronary artery disease, announced today that as part of the calendar year 2021...
Nov 18, 2020 08:00 am ET
Shockwave Medical to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Piper Sandler 32nd Annual Virtual...
Nov 09, 2020 04:05 pm ET
Shockwave Medical Reports Third Quarter 2020 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September...
Nov 07, 2020 10:05 am ET
Shockwave IVL Is Superior to Angioplasty in Severely Calcified Peripheral Artery Disease
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, reported today that investigators unveiled data from the Disrupt PAD...
Oct 22, 2020 04:05 pm ET
Shockwave Medical Announces VIVA20 Investor Update and Conference Call Discussing Third Quarter 2020 Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease will webcast an investor update at the virtual VIVA20 on Saturday,...
Oct 20, 2020 08:00 am ET
Shockwave Disrupt PAD III Results to be Presented in Late-Breaking Session at VIVA20
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the acute results from the DISRUPT PAD III...
Oct 15, 2020 12:35 pm ET
Shockwave IVL Meets Safety and Effectiveness Endpoints in U.S. Coronary Pivotal IDE Study
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the coronary Investigational Device Exemption...
Oct 01, 2020 08:00 am ET
Shockwave Announces Updated Time for CAD III Investor Webcast Event in Conjunction with TCT Connect
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced updated timing for the company’s CAD III Investor...
Sep 15, 2020 08:00 am ET
Shockwave Coronary IVL U.S. Pivotal Study Results to be Presented in Late-Breaking Session at TCT Connect
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the pivotal results from the  DISRUPT CAD III...
Aug 26, 2020 08:00 am ET
Shockwave Medical to Participate in Upcoming September Investor Conferences
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Shockwave management is scheduled to speak at the following upcoming...
Aug 11, 2020 04:05 pm ET
Shockwave Medical Reports Second Quarter 2020 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30,...
Jul 30, 2020 08:00 am ET
Shockwave Medical to Present at the Canaccord Genuity 40th Annual Growth Conference
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Canaccord Genuity 40th Annual Growth...
Jul 21, 2020 04:05 pm ET
Shockwave Medical to Report Second Quarter 2020 Financial Results on August 11, 2020
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the second quarter...
Jul 20, 2020 08:00 am ET
Shockwave Appoints Maria Sainz to Board of Directors
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Maria Sainz has joined its Board of Directors and will serve on...
Jul 08, 2020 04:33 pm ET
Shockwave Announces Decisions From the U.S. Patent and Trademark Office on Inter Partes Review Proceeding
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company received the initial rulings related to two of the inter...
Jun 16, 2020 08:20 pm ET
Shockwave Announces Pricing of Public Offering of Common Stock
Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced the pricing of its public offering of 1,700,000 shares of its common stock at a price to the public of $45.75 per share. All of the shares are being offered by Shockwave. The...
Jun 16, 2020 07:39 am ET
Shockwave Announces Proposed Public Offering of Common Stock
Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced it has commenced an underwritten public offering of 1,700,000 shares of its common stock. All of the shares of common stock are being offered by Shockwave. In addition, Shockwave...
Jun 08, 2020 04:30 pm ET
Shockwave Medical Announces That CMS Has Created New Codes for Intravascular Lithotripsy
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the Centers for Medicare & Medicaid Services (CMS)...
May 12, 2020 04:03 pm ET
Shockwave Medical Reports First Quarter 2020 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31,...
Apr 30, 2020 08:00 am ET
Shockwave Medical to Present at the Bank of America Securities 2020 Health Care Conference
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced today that the company will be participating in the upcoming Bank of America...
Apr 21, 2020 04:05 pm ET
Shockwave Medical to Report First Quarter 2020 Financial Results on May 12, 2020
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the first quarter...
Apr 13, 2020 08:00 am ET
Shockwave Completes Enrollment of Coronary Intravascular Lithotripsy Study in Japan
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company has completed enrollment in their DISRUPT CAD IV study of...
Apr 06, 2020 08:00 am ET
SHOCKWAVE COMPLETES ENROLLMENT IN PIVOTAL STUDY FOR CORONARY INTRAVASCULAR LITHOTRIPSY
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company has completed enrollment in the...
Feb 13, 2020 04:03 pm ET
Shockwave Medical Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Financial Outlook
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year...
Jan 21, 2020 04:05 pm ET
Shockwave Medical to Report Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the fourth quarter...
Nov 14, 2019 10:00 pm ET
Shockwave Announces Pricing of Public Offering of Common Stock
Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced the pricing of its public offering of 2,481,781 shares of its common stock at a price to the public of $36.25 per share. All of the shares are being offered by Shockwave. The...
Nov 12, 2019 04:13 pm ET
Shockwave Announces Proposed Public Offering of Common Stock
Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares of common stock are being offered by Shockwave. In addition,...
Nov 08, 2019 08:30 am ET
Shockwave Medical to Participate in the 13th Annual Canaccord Genuity Medical Technologies & Diagnostics Forum
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced the company will participate in a fireside chat with...
Nov 07, 2019 04:03 pm ET
Shockwave Medical Reports Third Quarter 2019 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September...
Nov 07, 2019 08:30 am ET
Shockwave Initiates Study of Coronary Intravascular Lithotripsy in Japan
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company has initiated the DISRUPT CAD IV study of IVL in heavily...
Nov 04, 2019 08:30 am ET
Shockwave Announces Commercial Availability of Below-the-Knee IVL Catheter
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced commercial availability of the Shockwave S4 Peripheral IVL Catheter in select...
Oct 17, 2019 04:03 pm ET
Shockwave Medical to Report Third Quarter 2019 Financial Results on November 7, 2019
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the third quarter...
Sep 25, 2019 11:00 am ET
Shockwave Study Demonstrates Strong Safety and Procedural Success of Coronary IVL in Europe
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, unveiled the results of the DISRUPT CAD II study, a European post-market study of coronary...
Sep 03, 2019 08:30 am ET
Shockwave Receives FDA Breakthrough Device Designation for the Coronary IVL System
Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced that the company has received Breakthrough Device Designation from the...
Aug 21, 2019 08:30 am ET
Shockwave Medical to Participate in Upcoming Investor Conferences
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced the company will be participating in two upcoming...
Aug 05, 2019 04:03 pm ET
Shockwave Medical Reports Second Quarter 2019 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30,...
Jul 23, 2019 04:03 pm ET
Shockwave Medical to Participate in the 39th Annual Canaccord Genuity Global Growth Conference
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced the company will participate in a fireside chat with...
Jul 23, 2019 04:03 pm ET
Shockwave Medical to Report Second Quarter 2019 Financial Results on August 5, 2019
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the second quarter...
Jun 10, 2019 08:00 am ET
Shockwave Appoints Hajime Tada as General Counsel
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the Company has appointed Hajime Tada as General...
May 15, 2019 08:00 am ET
Shockwave Appoints Keith D. Dawkins M.D. as Chief Medical Officer
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the Company has appointed Keith D. Dawkins, M.D....
May 08, 2019 04:03 pm ET
Shockwave Medical Reports First Quarter 2019 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31,...
May 01, 2019 08:30 am ET
Shockwave Medical to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced the company will be participating in the upcoming Bank...
Apr 24, 2019 08:30 am ET
Shockwave Medical to Report First Quarter 2019 Financial Results on May 8, 2019
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the first quarter...
Apr 03, 2019 08:00 am ET
Shockwave Completes Enrollment of Disrupt CAD II Study
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, has completed enrollment of its DISRUPT CAD II study, a...
Mar 11, 2019 04:10 pm ET
ShockWave Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ShockWave Medical, Inc. (“ShockWave”) (Nasdaq: SWAV), today announced the closing of its initial public offering of 6,555,000 shares of its common stock at an initial public offering price of $17.00 per share, including 855,000 shares sold pursuant...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.